Anthera Announces That Data From the Phase 2 BRIGHT-SC Study Has Been Accepted as a Late Breaking Abstract at the ASN Kidney Week 2016 Annual Meeting

HAYWARD, Calif., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) today announced that an abstract of the interim data from the Phase 2 BRIGHT-SC clinical study evaluating the treatment effect of blisibimod in patients with biopsy-proven IgA Nephropathy (IgAN) has been accepted as a late-breaking poster presentation at the 2016 American Society of Nephrology’s Kidney Week Annual Meeting.

“These data provide hope to patients with IgAN, for whom no approved therapy exists, that a targeted therapy may slow disease progression,” said Jonathan Barratt, MD, Reader in the Department of Infection, Immunity & Inflammation, University of Leicester, Honorary Consultant Nephrologist at Leicester General Hospital, and Head of the Postgraduate Specialty School of Clinical Academic Training at Health Education East Midlands.

“The observations from the BRIGHT-SC study provide clear evidence of blisibimod’s effects on proteinuria, B cells and immunoglobulins which are central to disease pathology, and support the hypothesis that B-cell activation underlies kidney damage. We are pleased to have this opportunity to share these data with the nephrology community,” said Renee Martin, Anthera’s Senior Vice President of Medical Sciences.

The poster entitled, “Effects of Blisibimod, a Selective Inhibitor of B-Cell Activating Factor, in Patients with IgA Nephropathy” is scheduled to be presented by Dr. Barratt on Friday, November 18, from 10 AM to 12 PM (Central Time).

The abstract will be available online at and the poster will be available on the Anthera website after completion of the session.

About Anthera Pharmaceuticals, Inc.

Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious and life-threatening diseases, including lupus, lupus with glomerulonephritis, IgA nephropathy, and exocrine pancreatic insufficiency due to cystic fibrosis. Additional information on the Company can be found at

Safe Harbor Statement

Any statements contained in this press release that refer to future events or other non-historical matters, including statements that are preceded by, followed by, or that include such words as "estimate," "intend," "anticipate," "believe," "plan," "goal," "expect," "project," or similar statements, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on Anthera's expectations as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially as set forth in Anthera's public filings with the SEC, including Anthera's Quarterly Report on Form 10-Q for the quarter ended June 30, 2016. Anthera disclaims any intent or obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law.

Contact Information: Nikhil Agarwal of Anthera Pharmaceuticals, Inc., or 510.856.5600 x5621

Source:Anthera Pharmaceuticals, Inc.